In this video, Michael Cameron, MD, shares four years of data on TYK2 inhibition in psoriasis care, highlighting the durability and safety that continue to reinforce confidence in this once-daily oral therapy. He explains how TYK2’s selective allosteric mechanism differentiates it from traditional JAK inhibitors—helping to account for its clean long-term safety profile—and discusses where oral therapy fits into practice today. With insights on sustained PASI responses, special-site efficacy, and real-world convenience, Dr. Cameron outlines why TYK2 inhibition remains a distinct and durable option for systemic-eligible patients.